331 related articles for article (PubMed ID: 8895149)
1. Anti-PM/Scl autoantibodies in patients without clinical polymyositis or scleroderma.
Schnitz W; Taylor-Albert E; Targoff IN; Reichlin M; Scofield RH
J Rheumatol; 1996 Oct; 23(10):1729-33. PubMed ID: 8895149
[TBL] [Abstract][Full Text] [Related]
2. Novel aspects of autoantibodies to the PM/Scl complex: clinical, genetic and diagnostic insights.
Mahler M; Raijmakers R
Autoimmun Rev; 2007 Aug; 6(7):432-7. PubMed ID: 17643929
[TBL] [Abstract][Full Text] [Related]
3. Serological and clinical characterization of anti-dsDNA and anti-PM/Scl double-positive patients.
Mahler M; Greidinger EL; Szmyrka M; Kromminga A; Fritzler MJ
Ann N Y Acad Sci; 2007 Aug; 1109():311-21. PubMed ID: 17785320
[TBL] [Abstract][Full Text] [Related]
4. C1D is a major autoantibody target in patients with the polymyositis-scleroderma overlap syndrome.
Schilders G; Egberts WV; Raijmakers R; Pruijn GJ
Arthritis Rheum; 2007 Jul; 56(7):2449-54. PubMed ID: 17599775
[TBL] [Abstract][Full Text] [Related]
5. Clinical implications of autoantibody screening in patients with autoimmune myositis.
Ghirardello A; Zampieri S; Tarricone E; Iaccarino L; Bendo R; Briani C; Rondinone R; Sarzi-Puttini P; Todesco S; Doria A
Autoimmunity; 2006 May; 39(3):217-21. PubMed ID: 16769655
[TBL] [Abstract][Full Text] [Related]
6. Anti-signal recognition particle autoantibody in patients with and patients without idiopathic inflammatory myopathy.
Kao AH; Lacomis D; Lucas M; Fertig N; Oddis CV
Arthritis Rheum; 2004 Jan; 50(1):209-15. PubMed ID: 14730618
[TBL] [Abstract][Full Text] [Related]
7. Anti-pm/scl antibodies in connective tissue disease: Clinical and biological assessment of 14 patients.
Vandergheynst F; Ocmant A; Sordet C; Humbel RL; Goetz J; Roufosse F; Cogan E; Sibilia J
Clin Exp Rheumatol; 2006; 24(2):129-33. PubMed ID: 16762146
[TBL] [Abstract][Full Text] [Related]
8. Anti-PM/Scl antibodies are found in Japanese patients with various systemic autoimmune conditions besides myositis and scleroderma.
Muro Y; Hosono Y; Sugiura K; Ogawa Y; Mimori T; Akiyama M
Arthritis Res Ther; 2015 Mar; 17(1):57. PubMed ID: 25885224
[TBL] [Abstract][Full Text] [Related]
9. [Spectrum of antinuclear and anti-cytoplasmic antibodies in dermatomyositis and polymyositis overlap syndromes].
Meurer M; Hausmann-Martinez-Pardo G; Braun-Falco O
Hautarzt; 1989 Oct; 40(10):623-9. PubMed ID: 2482267
[TBL] [Abstract][Full Text] [Related]
10. PM-Scl-75 is the main autoantigen in patients with the polymyositis/scleroderma overlap syndrome.
Raijmakers R; Renz M; Wiemann C; Egberts WV; Seelig HP; van Venrooij WJ; Pruijn GJ
Arthritis Rheum; 2004 Feb; 50(2):565-9. PubMed ID: 14872500
[TBL] [Abstract][Full Text] [Related]
11. Simultaneous presence of neutrophil alveolitis and Ki-67 positivity of alveolar macrophages in dermato-/polymyositis and systemic sclerosis.
Kumánovics G; Magyarlaki T; Komócsi A; Szekeres G; Czirják L
Rheumatol Int; 2003 Jan; 23(1):6-10. PubMed ID: 12548435
[TBL] [Abstract][Full Text] [Related]
12. PM1-Alpha ELISA: the assay of choice for the detection of anti-PM/Scl autoantibodies?
Mahler M; Fritzler MJ
Autoimmun Rev; 2009 Mar; 8(5):373-8. PubMed ID: 19103309
[TBL] [Abstract][Full Text] [Related]
13. Clinical evaluation of autoantibodies to a novel PM/Scl peptide antigen.
Mahler M; Raijmakers R; Dähnrich C; Blüthner M; Fritzler MJ
Arthritis Res Ther; 2005; 7(3):R704-13. PubMed ID: 15899056
[TBL] [Abstract][Full Text] [Related]
14. Clinical and serologic correlates of anti-PM/Scl antibodies in systemic sclerosis: a multicenter study of 763 patients.
D'Aoust J; Hudson M; Tatibouet S; Wick J; ; Mahler M; Baron M; Fritzler MJ
Arthritis Rheumatol; 2014 Jun; 66(6):1608-15. PubMed ID: 24577935
[TBL] [Abstract][Full Text] [Related]
15. Clinical and serological heterogeneity in patients with anticentromere antibodies.
Miyawaki S; Asanuma H; Nishiyama S; Yoshinaga Y
J Rheumatol; 2005 Aug; 32(8):1488-94. PubMed ID: 16078324
[TBL] [Abstract][Full Text] [Related]
16. [Clinical significance of anti-nucleolar antibodies detected by immunoprecipitation method in patients with systemic sclerosis].
Kuwana M; Mimori T; Hama N; Kaburaki J; Okano T; Tojo T
Ryumachi; 1992 Feb; 32(1):39-46. PubMed ID: 1604415
[TBL] [Abstract][Full Text] [Related]
17. Long-term outcome of patients with polymyositis/ dermatomyositis and anti-PM-Scl antibody.
Marie I; Lahaxe L; Benveniste O; Delavigne K; Adoue D; Mouthon L; Hachulla E; Constans J; Tiev K; Diot E; Levesque H; Boyer O; Jouen F
Br J Dermatol; 2010 Feb; 162(2):337-44. PubMed ID: 19845665
[TBL] [Abstract][Full Text] [Related]
18. Immunoserological aspects of idiopathic inflammatory muscle disease.
Rozman B; Bozic B; Kos-Golja M; Plesivcnik-Novljan M; Kveder T
Wien Klin Wochenschr; 2000 Aug; 112(15-16):722-7. PubMed ID: 11020964
[TBL] [Abstract][Full Text] [Related]
19. Effective use of autoantibody tests in the diagnosis of systemic autoimmune disease.
Lyons R; Narain S; Nichols C; Satoh M; Reeves WH
Ann N Y Acad Sci; 2005 Jun; 1050():217-28. PubMed ID: 16014537
[TBL] [Abstract][Full Text] [Related]
20. Immunolocalization and partial characterization of a nucleolar autoantigen (PM-Scl) associated with polymyositis/scleroderma overlap syndromes.
Reimer G; Scheer U; Peters JM; Tan EM
J Immunol; 1986 Dec; 137(12):3802-8. PubMed ID: 3537125
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
